Shandong Pureman Pharmaceutical Co., Ltd.

Primary study objective To evaluate the pharmacokinetic characteristics and bioequivalence of a single oral dose of the test azithromycin dry suspension formulation (specification: 0.1 g, applicant: Shandong Pu Rui Man Pharmaceutical Co., Ltd.) and the reference formulation (trade name: Xi Shu Mei ®, specification: 0.1 g, licensee: Pfizer Pharmaceuticals Co., Ltd.) in healthy Chinese adult subjects under fasting and fed conditions. Secondary study objective To study the safety of the test azithromycin dry suspension formulation (specification: 0.1 g) and the reference formulation (trade name: Xi Shu Mei ®, specification: 0.1 g) in healthy Chinese adult subjects.

The main purpose of the study is to use AstraZeneca AB's licensed dapagliflozin tablets (trade name: Andatang) as the reference preparation and Shandong Pu Ruiman Pharmaceutical Co., Ltd.'s dapagliflozin tablets as the test preparation to evaluate the human bioequivalence of the two preparations through a single-center, randomized, open, single-dose, two-cycle, double-crossover clinical study. Secondary purpose of the study: to observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

The primary study objective was to evaluate the bioequivalence of escitalopram oxalate tablets (10 mg/tablet) produced by Shandong Pu Rui Man Pharmaceutical Co., Ltd. and escitalopram oxalate tablets (trade name: Lexapro®, 10 mg/tablet) certified by H. Lundbeck A/S in healthy Chinese subjects after single oral administration on an empty stomach or after meals. The secondary study objective was to evaluate the safety of the test and reference preparations in healthy Chinese adult subjects.